Asthma and COPD Therapies: World Market 2011-2021

News provided by

Sep 26, 2011, 04:01 ET

NEW YORK, Sept. 26, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Asthma and COPD Therapies: World Market 2011-2021

http://www.reportlinker.com/p0629350/Asthma-and-COPD-Therapies-World-Market-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory

Report Details

How will the market for asthma and COPD treatments perform from 2011? Our new report shows you potential drug revenues to 2021, discussing opportunities and market prospects.

Discover potential asthma and COPD drug revenues at total world, company, product and national levels. Through our research and analysis we aim to save you time and help in your decisions.

How will competition affect the asthma and COPD treatment market? We show you how drugs such as Seretide/Advair, Singulair, Spiriva, Symbicort, Combivent and Pulmicort can perform to 2021. Receive data you need.

Find market prospects and outlooks for GSK, Merck, Boehringer Ingelheim, AstraZeneca, Novartis and Nycomed. Discover revenue forecasts.

Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.

Analysis with revenues, future growth rates, market shares, opinions and discussions

In our report you find revenue forecasts, growth rates, market shares, a SWOT/STEP review, an R&D review and opinion from our survey. You receive 111 tables and charts and a research interview (shown in the accompanying lists).

Asthma and COPD Therapies: World Market 2011-2021 shows you opportunities, challenges and revenue forecasts

Our report gives you the following advantages:

• Find revenue predictions to 2021 for the world asthma and COPD drug market, seeing revenue growth

• Discover revenue forecasts to 2021 for leading products, assessing market potentials

• Assess leading companies, discovering their revenue prospects to 2021

• See revenue forecasts to 2021 for leading national markets - US, Japan, Germany, France, UK, Spain, Italy, China and India

• Review R&D for asthma and COPD, assessing potential

• Investigate competition and opportunities influencing the industry and market

• See what will stimulate and restrain the industry and market from 2011

• View opinion from our survey of the asthma and COPD field.

There, you find a distinctive mix of quantitative and qualitative analysis with independent predictions. We tackle crucial questions in asthma and COPD, helping you to stay ahead.

Order our report now to gain industry and market analysis for asthma and COPD

Our report is for everybody needing industry and market analysis for asthma and COPD treatments. Find trends and answers. Avoid missing out - please order our report now.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6

Companies Listed

American Academy of Allergy, Asthma & Immunology

American Thoracic Society

Apotex

Applied Molecular Evolution

Arrow Group

Astellas

Asthma UK

AstraZeneca

Bayer Schering Pharma

Biocryst

Boehringer Ingelheim

Breath

British Lung Foundation

Centers for Disease Control and Prevention

Centers for Medicare and Medicaid Services

Chugai

Cipla

Daiichi Sankyo

Dainippon Sumitomo

Dr. Reddy's Laboratories

Eli Lilly

European Federation of Allergy and Airways Diseases

European Medicines Agency (EMA)

European Patent Office

Food and Drug Administration (US FDA)

Genentech

GeoPharm

GlaxoSmithKline

Hetero Drugs

Johnson & Johnson

Kyorin

MedImmune

Merck & Co.

Mylan

National Heart, Lung and Blood Institute

Novartis

Nycomed

Olmsted Medical Center

Ono Pharmaceuticals

Orchid Pharmaceuticals

Perrigo

Pfizer

Pulmagen Therapeutics (Synergy)

Ranbaxy

Roche

Sandoz

Sanofi

Schering-Plough

Sepracor

Shanghai Pharmaceuticals

SkyePharma

Tanox Biosystems

Teva Pharmaceutical Industries

Theravance

University of Minnesota

US Centers for Disease Control

World Health Organization (WHO)

Wyeth (now part of Pfizer)

Table of Contents

1. Executive Summary

1.1 Asthma & COPD Market Review

1.2 Aims, Scope and Format of the Report

1.3 Research and Analysis Methods

2. Introduction to Asthma & COPD Therapies

2.1 Introduction

2.1.1 The Asthma & COPD Market

2.2 Overview of Respiratory Disorders

2.3 Asthma

2.3.1 Causes and Triggers of Asthma

2.3.2 Increasing Prevalence

2.3.3 High Economic Cost

2.3.4 Treatments for Asthma

2.3.5 Delivery Method - Types of Inhaler

2.4 Chronic Obstructive Pulmonary Disease (COPD)

2.4.1 Symptoms of COPD

2.4.2 Management of COPD

2.4.3 COPD on the Rise

2.4.4 The Economic Burden of COPD

2.5 Major Drug Classes in Treating Respiratory Diseases

2.5.1 Combination Drugs

2.5.2 Leukotriene Inhibitors

2.5.3 Corticosteroids

2.5.4 Beta-2 (Adrenoreceptor) Agonists

2.5.5 Antihistamines

2.5.6 Monoclonal Antibodies

3. The Asthma & COPD Therapies Market, 2011-2021

3.1 The World Asthma & COPD Therapies Market in 2010

3.2 Growing Market for Asthma & COPD Drug Treatments

3.2.1 Sales Forecast for Asthma & COPD Therapies, 2011-2015

3.3 Leading Companies in Asthma & COPD Therapies Market

3.3.1 GSK Sales Forecast for Asthma & COPD Therapies Market, 2011-2015

3.3.2 GSK Sales Forecast for Asthma & COPD Therapies Market, 2016-2021

3.3.3 Merck Sales Forecast for Asthma & COPD Therapies Market, 2011-2015

3.3.4 Merck Sales Forecast for Asthma & COPD Therapies Market, 2016-2021

3.3.5 Boehringer Ingelheim Sales Forecast for Asthma & COPD Therapies Market, 2011-2015

3.3.6 Boehringer Ingelheim Sales Forecast for Asthma & COPD Therapies Market, 2016-2021

3.3.7 AstraZeneca Sales Forecast for Asthma & COPD Therapies Market, 2011-2015

3.3.8 AstraZeneca Sales Forecast for Asthma & COPD Therapies Market, 2016-2021

3.3.9 Novartis Sales Forecast for Asthma & COPD Therapies Market, 2011-2015

3.3.10 Novartis Sales Forecast for Asthma & COPD Therapies Market, 2016-2021

3.3.11 Nycomed Sales Forecast for Asthma & COPD Therapies Market, 2011-2015

3.3.12 Nycomed Sales Forecast for Asthma & COPD Therapies Market, 2016-2021

3.3.13 Summary: Leading Companies in Asthma & COPD Therapies Market, 2011-2021

3.4 Asthma & COPD Therapies: Leading National Markets, 2011-2021

3.4.1 The US Asthma & COPD Therapies Market, 2011-2021

3.4.2 The Japanese Asthma & COPD Therapies Market, 2011-2021

3.4.3 The Leading European Asthma & COPD Therapies Markets, 2011-2021

3.4.4 Emerging-Economy Asthma & COPD Therapies Markets

3.4.5 The Chinese Asthma & COPD Therapies Market, 2011-2021

3.4.6 The Indian Asthma & COPD Therapies Market, 2011-2021

3.5 Summary of Market Forecasts

4. GlaxoSmithKline's Contribution to the Asthma & COPD Market

4.1 Introduction

4.2 Leading Products

4.3 Sales Forecasts for Leading Products, 2011-2021

4.3.1 Seretide/Advair: Sales, 2010

4.3.1.1 Seretide/Advair: Sales Forecast, 2011-2015

4.3.1.2 Seretide/Advair: Sales Forecast, 2016-2021

4.3.2 Flixotide/Flovent

4.3.2.1 Flixotide/Flovent Sales Forecast, 2011-2015

4.3.2.2 Flixotide/Flovent Sales Forecast, 2016-2021

4.3.3 Ventolin

4.3.3.1 Ventolin Sales Forecast, 2011-2015

4.3.3.2 Ventolin Sales Forecast, 2016-2021

4.3.4 Serevent

4.3.4.1 Serevent Sales Forecast, 2011-2015

4.3.4.2 Serevent Sales Forecast, 2016-2021

4.3.5 Summary: GSK Asthma & COPD Therapies: Sales, 2011-2021

4.4 GSK Asthma & COPD Pipeline Products, 2011

4.5 Summary: GSK Dominates Asthma & COPD Market

5. Merck's Contribution to the Asthma & COPD Market

5.1 Introduction

5.2 Leading Products

5.3 Sales Forecasts for Leading Products, 2011-2021

5.3.1 Singulair: Sales, 2010

5.3.1.1 Competitors from Other Drug Categories

5.3.1.2 Singulair and Safety Concerns

5.3.1.3 Singulair Patent Expiry Looms for Merck

5.3.1.4 Singulair Sales Forecast, 2011-2015

5.3.1.5 Singulair Sales Forecast, 2016-2021

5.3.2 Proventil HFA

5.3.2.1 Proventil HFA Sales Forecast, 2011-2015

5.3.2.2 Proventil HFA Sales Forecast, 2016-2021

5.3.3 Asmanex Twisthaler

5.3.3.1 Asmanex Twisthaler: Sales Forecast, 2011-2015

5.3.3.2 Asmanex Twisthaler: Sales Forecast, 2016-2021

5.3.4 Summary: Merck Asthma & COPD Therapies: Sales, 2011-2021

5.4 Merck Asthma & COPD Pipeline Products, 2011

5.5 Summary: Merck Reliant on Singulair in Asthma & COPD Market

6. Boehringer Ingelheim's Contribution to the Asthma & COPD Market

6.1 Introduction

6.2 Leading Products

6.3 Sales Forecasts for Leading Products, 2011-2021

6.3.1 Spiriva Demonstrates Strong Growth, 2010

6.3.1.1 Safety Concerns and the UPLIFT Trial

6.3.1.2 Results of the POET Study

6.3.1.3 Competition and Other Restraints

6.3.1.4 Spiriva: Sales Forecast, 2011-2015

6.3.1.5 Spiriva: Sales Forecast, 2016-2021

6.3.2 Combivent

6.3.2.1 Will the Leading Position Last?

6.3.2.2 Combivent Sales Forecast, 2011-2015

6.3.2.3 Combivent Sales Forecast, 2016-2021

6.3.3 Summary: Boehringer Ingelheim Asthma & COPD Therapies: Sales, 2011-2021

6.4 Boehringer Ingelheim Asthma & COPD Pipeline Products, 2011

6.5 Summary: Boehringer Ingelheim - Strong Presence in the Asthma & COPD Market

7. AstraZeneca's Contribution to the Asthma & COPD Market

7.1 Introduction

7.2 Leading Products

7.3 Sales Forecasts for Leading Products, 2011-2021

7.3.1 Symbicort: Leading the Market, 2010

7.3.1.1 Symbicort and the COPD Indication

7.3.1.2 Symbicort: The SMART Concept

7.3.1.3 Symbicort: Sales Forecast, 2011-2015

7.3.1.4 Symbicort: Sales Forecast, 2016-2021

7.3.2 Pulmicort

7.3.2.1 Delivery Methods

7.3.2.2 Challenges for Pulmicort: Are They Insurmountable?

7.3.2.3 Pulmicort Sales Forecast, 2011-2015

7.3.2.4 Pulmicort Sales Forecast, 2016-2021

7.3.3 Summary: AstraZeneca Asthma & COPD Therapies: Sales, 2011-2021

7.4 AstraZeneca Asthma & COPD Pipeline Products, 2011

7.5 Summary: AstraZeneca Hopes to Build on Symbicort in Asthma & COPD Market

8. Novartis' Contribution to the Asthma & COPD Market

8.1 Introduction

8.2 Leading Products

8.3 Sales Forecasts for Leading Products, 2011-2021

8.3.1 Xolair Exhibits Strong Growth, 2010

8.3.1.1 Xolair Sales Forecast, 2011-2015

8.3.1.2 Xolair Sales Forecast, 2016-2021

8.3.2 Onbrez Breezhaler

8.3.2.1 US Launch Under Brand Name Arcapta Neohaler Expected in 2011

8.3.2.2 Onbrez Breezhaler Sales Forecast, 2011-2015

8.3.2.3 Onbrez Breezhaler Sales Forecast, 2016-2021

8.3.3 Summary: Novartis Asthma & COPD Therapies: Sales, 2011-2021

8.4 Novartis Asthma & COPD Pipeline Products, 2011

8.5 Summary: Novartis - Growing Presence in Asthma & COPD Market

9. SWOT Analysis: Factors Influencing the Market

9.1 Introduction

9.2 Asthma & COPD Therapeutics: A Key Sector in Respiratory Diseases

9.3 Commercial Drivers of the Asthma Therapies Market

9.3.1 Expanding Patient Population

9.3.2 High Economic Costs of Respiratory Diseases

9.3.3 Changing Perception of COPD

9.3.4 Educating the Masses: Understanding the Severity of Respiratory Disease

9.3.5 Management Rather than Cure

9.3.6 Lifecycle Management Strategies to Counter Patent Expiry

9.3.7 Brand Awareness

9.3.8 Inhalable Systems: DPI and pMDI Gain Momentum

9.4 Principal Restraints for Respiratory Therapeutics

9.4.1 The Threat of Generics

9.4.2 Restrictions on Healthcare Budgets Favour the Use of Generics

9.4.3 Purchasers Hold Increased Bargaining Power

9.4.4 Maturation of the Market

9.5 Research Interview: Dr Barbara Yawn, MD, Director of Research, Olmsted Medical Center, and Adjunct Professor, Department of Family and Community Health, University of Minnesota, USA

9.5.1 On Key Unmet Needs

9.5.2 Asthma/COPD R&D Focus in the Future

9.5.3 Main Challenges Facing Asthma & COPD Research

9.5.4 Advantages & Disadvantages of Current Asthma & COPD Therapies

9.5.5 On Important Developments in the Sector

9.5.6 On Pipeline Developments in Asthma & COPD

9.6 Summary of Chapter: Market Drivers and Restraints

10. Conclusions from Our Study

10.1 Introduction

10.2 Leading Companies in the Market

10.3 Leading Products in Asthma and COPD Market, 2010

10.4 Combination Drugs Such as Seretide/Advair Continue to Dominate